Khramtsova I. O., Derbak M. A., Ganich T. M., Svistak V. V., Ganich O. T.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

Abstract. NASH is currently considered to be one of the most common causes of elevated liver tests without clinical symptoms. The aim of the research was to study the frequency of liver injury in patients with chronic obstructive pulmonary disease based on the results of non-invasive research methods. Materials and methods. A retrospective analysis of 479 case histories of inpatients who were treated at the Transcarpathian Regional Clinical Hospital named after Andriy Novak during 2018-2020 with a diagnosis of NAFLD and COPD or a combination of them was conducted. To determine the stage of steatosis and liver fibrosis used data from a non-invasive diagnostic method – FibroMax, which includes: FibroTest, ActiTest, SteatoTest, AshTest, NashTest. Results and discussion. After a detailed analysis of the obtained data, it was found that 45% of patients with COPD have diffuse liver damage. Statistical analysis showed that the high frequency of exacerbations of COPD leads to an increase of the number of combined liver injury. Thus, in patients with frequent exacerbations of COPD, a combination of steatosis, fibrosis and inflammation predominates, while in patients with a low frequency of exacerbations of COPD, steatosis without inflammation predominates (p<0.05). Decreased adiponectin content in patients with NAFLD who had frequent exacerbations of COPD correlated with the stages of liver steatosis (r=0.47; p<0.05) and increased leptin levels (29.5±1.71 ng/ml vs. 7.03±0.52 ng/ml, p<0.05). As blood leptin levels increase and the adiponectin / leptin ratio decreases, the degree of hepatic steatosis increases and its combination with fibrosis and inflammation. Conclusions. According to non-invasive research methods, it was found that almost half of patients with COPD (45%) have diffuse liver disease. In patients with frequent exacerbations of COPD, combined liver injury in the form of steatosis, fibrosis and inflammation predominate, while in patients with a low frequency of exacerbations of COPD, hepatic steatosis predominates.

Fibromax, nonalcoholic fatty liver disease, chronic obstructive pulmonary disease, non-invasive diagnostics.

1. Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. Journal of Hepatology. 2019;70:531-544.
2. Blond E, Disse E, Cuerq C, Drai J, Valette PJ, Laville M, et al. EASL–EASD–EASO clinical practice guidelines for the management of nonalcoholic fatty liver disease in severely obese people: do they lead to over-referral? Diabetologia, 2017;60(7):1218-1222.
3. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M, et al. Global epidemiology of nonalcoholic fatty liver disease – metaanalytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84.
4. Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J. Hepatol. 2017;9:715-732.
5. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. European Respiratory Journal. 2019;53(5):1-12.
6. Todoriko LD. Formuvannya sistemnih proyaviv ta viznachennya prediktoriv progresuvannya pri hronichnomu obstruktivnomu zahvoryuvanni legen za rezultatami faktornogo analizu. Ukrayinskiy pulmonologichniy zhurnal. 2019;(1):49-54. [in Ukrainian].
7. Tuleta I, Farrag T, Busse L, Pizarro C, Schaefer C, Pingel S, et al. High prevalence of COPD in atherosclerosis patients. International journal of chronic obstructive pulmonary disease. 2017;12:3047.
8. Cebron Lipovec N, Beijers RJ, van den Borst B, Doehner W, Lainscak M, Schols AM, et al. The prevalence of metabolic syndrome in chronic obstructiv pulmonary disease: a systematic review. COPD. 2016;13:399-406.
9. Viglino D, Jullian-Desayes I, Minoves M, Aron-Wisnewsky J, Leroy V, Zarski JP, et al. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease. Eur. Respir. J. 2017;49:1-9.
10. Treumova SI, Petrov EE, Boryak VP. Hronichne obstruktivne zahvoryuvannya legen u poednannI z metabolichnim sindromom. Visnik problem biologiyi i meditsini. 2015;1:33-36. [in Ukrainian].
11. Khukhlina OS, Hryniuk OY, Voievidka OS, Haidychuk VS, Mandryk OY, Kosar LY, et al. Clinical course features of non-alcoholic steatohepatitis on obesity background in comorbidity with chronic obstructive pulmonary disease. Bukovinian Medical Herald. 2020;1(93):158-165.

«Bulletin of problems biology and medicine» Issue 3 (161), 2021 year, 153-157 pages, index UDK 616.36-036.1:616.24-007.272

10.29254/2077-4214-2021-3-161-153-157